Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026

New single-arm, open-label data extend the body of evidence supporting consistent clinical benefit and safety with Camzyos, adding to the longest-running clinical development experience for a cardiac myosin inhibitor (CMI) in symptomatic oHCM

Additional presentations at ESC Congress build upon the established effectiveness and safety profile of Camzyos in real-world settings

PRINCETON, N.J., August 29, 2026--Bristol Myers Squibb (NYSE: BMY) today presented results from the EXPLORER-LTE cohort of the MAVA-LTE study (NCT03723655) in a late-breaker presentation at the European Society of Cardiology (ESC) Congress 2026 in Munich, Germany. EXPLORER-LTE is the largest and longest evaluation of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) patients treated with Camzyos, the most-studied cardiac myosin inhibitor (CMI) and a standard of care for patients with oHCM in New York Heart Association (NYHA) class II-III. These data add to the understanding that the effects of Camzyos are sustained for up to five years with continuous, consistent treatment. Additional presentations at ESC Congress from COLLIGO-HCM, a global retrospective real-world data study, add to the well-established real-world evidence supporting Camzyos, helping inform treatment decisions for people living with the condition.

"The EXPLORER-LTE data up to five years reflect the sustained and clinically meaningful effects of Camzyos for patients living with symptomatic oHCM," said Anjali T. Owens, MD, Medical Director of the Center for Inherited Cardiac Disease and an Associate Professor of Medicine in the Perelman School of Medicine at the University of Pennsylvania. "For a chronic, progressive condition that requires ongoing treatment and monitoring, long-term evidence is essential to helping clinicians better understand how a therapy may benefit patients over time."

EXPLORER-LTE is a single-arm, open-label, dose-blinded extension of the Phase 3 EXPLORER-HCM study, evaluating the long-term safety and efficacy of Camzyos. A total of 231 patients who completed EXPLORER-HCM enrolled in the long-term extension study. A substantial portion of patients experienced sustained and clinically meaningful reduction of left ventricular outflow tract (LVOT) obstruction, improved by at least one NYHA class and experienced notable improvements in echocardiographic measures and biomarkers. No new safety signals were observed that were not observed in the primary EXPLORER-HCM study.

At 252 weeks, Camzyos treatment resulted in mean changes from baseline at initiation of the long-term extension study of -38.7 mm Hg for resting LVOT gradient and -55.6 mm Hg in Valsalva LVOT gradient. Nearly all patients (97.4%) achieved a Valsalva LVOT gradient ≤ 30 mm Hg, which is the threshold for obstruction in patients with oHCM. 69.6% of patients improved by ≥1 NYHA class and 59.2% of patients were asymptomatic. Mean left ventricular ejection fraction (LVEF) decreased by 10.2% and remained within the normal range. Safety findings were consistent with reported results from the primary EXPLORER-HCM study.